Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention

키워드

참고문헌 (45)

1. Walensky RP, "The survival benefits of AIDS treatment in the United States", J Infect Dis, 194, pp.11~19 (2006)
2. Paterson DL, "Adherence to protease inhibitor therapy and outcomes in patients with HIV infection", Ann Intern Med, 133, pp.21~30 (2000)
3. Kishimoto T, "Long-acting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
4. Correll CU, "The use of long-acting injectable antipsychotics in Schizophrenia : Evaluating the evidence", J Clin Psychiatry, 77(Suppl 3), pp.1~24 (2016)
5. Williams J, "Longacting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients", Nanomedicine(Lond), 8, pp.1807~1813 (2013)
6. Weld ED, "Interest of youth living with HIV in long-acting antiretrovirals", J Acquir Immune Defic Syndr, 80, pp.190~197 (2019)
7. Davis W, "“It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain", PLoS One, 15, pp.e0232473~ (2020)
8. Rajoli RKR, "Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK", Eur J Pharm Biopharm, 144, pp.101~109 (2019)
9. Karmon SL, "GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1", J Acquir Immune Defic Syndr, 68, pp.e39~41 (2015)
10. Trezza C, "Formulation and pharmacology of long-acting cabotegravir", Curr Opin HIV AIDS, 10, pp.239~245 (2015)
11. Ford SL, "Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744", Antimicrob Agents Chemother, 57, pp.5472~5477 (2013)
12. Margolis DA, "Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial", Lancet Infect Dis, 15, pp.1145~1155 (2015)
13. Margolis DA, "Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection(LATTE-2) : 96-week results of a randomised, open-label, phase 2b, non-inferiority trial", Lancet, 390, pp.1499~1510 (2017)
14. "Safety, efficacy and durability of long-acting cabotegravir (CAB) and rilpivirine (RPV) as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 week 160 results"[URL]
15. Orkin C, "Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection", N Engl J Med, 382, pp.1124~1135 (2020)
16. Orkin C, "Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection : week 124 results of the open-label phase 3 FLAIR study", Lancet HIV, 8, pp.e668~78 (2021)
17. Swindells S, "Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression", N Engl J Med, 382, pp.1112~1123 (2020)
18. Swindells S, "Long-acting cabotegravir + rilpivirine for HIV-1 treatment : ATLAS week 96 results", AIDS (2021)
19. Overton ET, "Long-acting cabotegravir and rilpivirine dosed every 2months in adults with HIV-1 infection(ATLAS-2M), 48-week results : a randomised, multicentre, openlabel, phase 3b, non-inferiority study", Lancet, 396, pp.1994~2005 (2021)
20. "Compassionate use of long acting (LA)cabotegravir (CAB) and rilpivirine (RPV) for patients in need of parenteral antiretroviral therapy"[URL]
21. Letendre SL, "Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults", J Antimicrob Chemother, 75, pp.648~655 (2020)
22. "Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV"[URL]
23. Landovitz RJ, "Cabotegravir for HIV prevention in cisgender men and transgender women", N Engl J Med, 385, pp.595~608 (2021)
24. "Storage and stability of cabotegravir and rilpivirine suspensions for injection"[URL]
25. "Cabotergravir and rilpivirine PK following long-acting HIV treatment discontinuation"[URL]
26. "Annex 1: Summary of product characteristics"[URL]
27. Culhane J, "Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya", EClinicalMedicine, 25, pp.100453~ (2020)
28. Michailidis E, "Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor", J Biol Chem, 284, pp.35681~35691 (2009)
29. Markowitz M, "4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591 : a novel HIV-1 reverse transcriptase translocation inhibitor", Curr Opin HIV AIDS, 13, pp.294~299 (2018)
30. Stoddart CA, "Oral administration of the nucleoside EFdA(4′-ethynyl-2-fluoro-2′-deoxyadenosine)provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque", Antimicrob Agents Chemother, 59, pp.4190~4198 (2015)
31. Schürmann D, "Safety, pharmacokinetics, and antiretroviral activity of islatravir(ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1 : an open-label, phase 1b, consecutive-panel trial", Lancet HIV, 7, pp.e164~e172 (2020)
32. "Next-generation islatravir implants projected to provide yearly HIV prophylaxis"[URL]
33. Bleasby K, "Islatravir is not expected to be a victim or perpetrator of drug-drug interactions via major drug-metabolizing enzymes or transporters", Viruses, 13, pp.1566~ (2021)
34. Molina JM, "Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine : a phase 2b, randomised, double-blind, dose-ranging trial", Lancet HIV, 8, pp.e324~e333 (2021)
35. "Identifier: NCT05052996. Study evaluating the safety and efficacy of islatravir in combination with lenacapavir in virologically suppressed people with HIV"[URL]
36. "Identifier: NCT04644029. Oral ISL QM as PrEP in cisgender women at high risk for HIV-1 infection (MK-8591-022) (Impower-022)"[URL]
37. "Identifier: NCT04652700. Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Have Sex With Men and Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)"[URL]
38. Link JO, "Clinical targeting of HIV capsid protein with a long-acting small molecule", Nature, 584, pp.614~618 (2020)
39. Bester SM, "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor", Science, 370, pp.360~364 (2020)
40. Fernandez J, "Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating", Nat Microbiol, 4, pp.1840~1850 (2019)
41. "Identifier: NCT04150068. Study to evaluate the safety and efficacy of lenacapavir in combination with an optimized background regimen in heavily treatment experienced participants living with HIV-1 infection with multidrug resistance 2020"[URL]
42. "Identifier: NCT04143594. Study to evaluate the safety and efficacy of lenacapavir in combination with other antiretroviral agents in people living with HIV"[URL]
43. "Efficacy and safety of long-acting subcutaneous lenacapavir in phase 2/3 in heavily treatment-experienced people with HIV: week 26 results (Capella study)"[URL]
44. "Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2induction-maintenance study (CALIBRATE)"[URL]
45. "Identifier: NCT04925752. Study to assess the effectiveness and safety of lenacapvir for human immunodeficiency virus (HIV) Pre-exposure Prophylaxis (Purpose 2)"[URL]

관련 논문AI추천